CA2876252A1 - Biomarkers for prostate cancer - Google Patents

Biomarkers for prostate cancer Download PDF

Info

Publication number
CA2876252A1
CA2876252A1 CA2876252A CA2876252A CA2876252A1 CA 2876252 A1 CA2876252 A1 CA 2876252A1 CA 2876252 A CA2876252 A CA 2876252A CA 2876252 A CA2876252 A CA 2876252A CA 2876252 A1 CA2876252 A1 CA 2876252A1
Authority
CA
Canada
Prior art keywords
seq
nucleotide sequence
st6galnac3
hapln3
gas6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2876252A
Other languages
English (en)
French (fr)
Inventor
Karina Dalsgaard Sorensen
Christa HALDRUP
Torben Falck Orntoft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus University
Original Assignee
Aarhus University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus University filed Critical Aarhus University
Publication of CA2876252A1 publication Critical patent/CA2876252A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2876252A 2012-06-14 2013-06-14 Biomarkers for prostate cancer Pending CA2876252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270326 2012-06-14
DKPA201270326 2012-06-14
PCT/DK2013/050196 WO2013185779A2 (en) 2012-06-14 2013-06-14 Biomarkers for prostate cancer

Publications (1)

Publication Number Publication Date
CA2876252A1 true CA2876252A1 (en) 2013-12-19

Family

ID=48740787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2876252A Pending CA2876252A1 (en) 2012-06-14 2013-06-14 Biomarkers for prostate cancer

Country Status (6)

Country Link
US (1) US10106854B2 (enExample)
EP (1) EP2861759B1 (enExample)
JP (1) JP6242388B2 (enExample)
AU (1) AU2013275761B2 (enExample)
CA (1) CA2876252A1 (enExample)
WO (1) WO2013185779A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971179B1 (en) 2013-03-14 2019-01-09 Mayo Foundation for Medical Education and Research Detecting neoplasm
EP3037545A1 (en) * 2014-12-23 2016-06-29 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A DNA-methylation test for prostate cancer
WO2016160454A1 (en) 2015-03-27 2016-10-06 Exact Sciences Corporation Detecting esophageal disorders
JP6871926B2 (ja) 2015-08-31 2021-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチMayo Foundation for Medical Education and Research 胃の新生物を検出すること
CN106480169B (zh) * 2015-09-01 2019-10-08 杨小丽 人aqp10和sox17基因甲基化位点的检测和应用
US10934592B2 (en) * 2017-02-28 2021-03-02 Mayo Foundation For Medical Education And Research Detecting prostate cancer
GB201816820D0 (en) 2018-10-16 2018-11-28 Univ York Diagnostic method
EP3880846B1 (en) 2018-11-13 2024-08-28 Bracco Imaging SPA Gene signatures for the prediction of prostate cancer recurrence
CN109468381B (zh) * 2018-11-19 2022-11-25 兰州市第一人民医院 用于宫颈癌筛查的甲基化位点及其检测引物
EP3999662A1 (en) * 2019-07-19 2022-05-25 Vilnius University Characterization of prostate cancer using dna methylation assay system
CN113122634B (zh) * 2020-01-14 2026-03-10 江苏鹍远生物科技股份有限公司 检测dna甲基化的试剂及用途
CA3172143A1 (en) * 2020-05-04 2021-11-11 David A. Ahlquist Detecting pancreatic neuroendocrine tumors
US20230212684A1 (en) * 2020-05-05 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Cell-free dna biomarkers and their use in diagnosis, monitoring response to therapy, and selection of therapy for prostate cancer
CN118685523B (zh) * 2024-08-26 2024-11-15 湖南宏雅基因技术有限公司 一种用于前列腺癌检测的生物标志物组合、引物探针组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6605432B1 (en) 1999-02-05 2003-08-12 Curators Of The University Of Missouri High-throughput methods for detecting DNA methylation
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US20100297067A1 (en) 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
EP2329041A1 (en) 2008-08-05 2011-06-08 Veridex, LLC Prostate cancer methylation assay
ES2595410T3 (es) * 2009-01-07 2016-12-29 Myriad Genetics, Inc. Biomarcadores de cáncer
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011037936A2 (en) * 2009-09-24 2011-03-31 Oregon Health & Science University Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer
WO2011044902A1 (en) 2009-10-13 2011-04-21 Aarhus Universitet Tff3 hypomethylation as a novel biomarker for prostate cancer
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2012138609A2 (en) * 2011-04-04 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methylation biomarkers for diagnosis of prostate cancer

Also Published As

Publication number Publication date
AU2013275761B2 (en) 2017-09-28
EP2861759B1 (en) 2025-06-04
WO2013185779A3 (en) 2014-02-06
EP2861759A2 (en) 2015-04-22
WO2013185779A2 (en) 2013-12-19
US20150152507A1 (en) 2015-06-04
JP6242388B2 (ja) 2017-12-06
AU2013275761A1 (en) 2015-01-22
JP2015527875A (ja) 2015-09-24
US10106854B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
US10106854B2 (en) Biomarkers for prostate cancer
Chimonidou et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients
JP2020513795A (ja) 前立腺癌検出
US20140094380A1 (en) Methylation Biomarkers for Diagnosis of Prostate Cancer
US12252747B2 (en) Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
WO2012154979A2 (en) Method of detecting cancer through generalized loss of stability of epigenetic domains, and compositions thereof
WO2012098215A1 (en) Epigenetic portraits of human breast cancers
US12071672B2 (en) Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
CN111440863B (zh) Kazn基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用
Kim et al. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
ES3036448T3 (en) A dna-methylation test for prostate cancer
US20120135877A1 (en) DNA Methylation Markers For Prostate Cancer Field Defect
US20090186360A1 (en) Detection of GSTP1 hypermethylation in prostate cancer
Ross et al. Identification of differentially methylated regions using streptavidin bisulfite ligand methylation enrichment (SuBLiME), a new method to enrich for methylated DNA prior to deep bisulfite genomic sequencing
US20180179597A1 (en) Cancer markers
EP2978861B1 (en) Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
KR101273569B1 (ko) 전립선암 특이적 유전자의 메틸화 검출 방법 및 이의 용도
Leong Development of epigenetic-based prognostic biomarkers to stratify risk of recurrence in early rectal cancer
WO2009134468A2 (en) Detecting prostate cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180503

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240717

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804